MRIGlobal to support pre-clinical drug development and manufacture for National Institutes of Health National Center for Advancing Translational Sciences (NCATS).
KANSAS CITY, Mo., May 2, 2017 — MRIGlobal today announced the award of a five-year program from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The program will support the Division of Pre-Clinical Innovation (DPI) efforts for pre-clinical drug development.
Within NCATS, the DPI plans and conducts advanced collaborative research projects across the pre-clinical phases of translational science.
MRIGlobal will supply services related to synthesis and analysis of small molecules, and will provide support for manufacture and analysis of small molecules; process chemistry optimization; API (active pharmaceutical ingredients) characterization; analytical method validation; and controlled stability studies.
“MRIGlobal is honored to continue our support of the important work within NCATS to develop new therapies,” said Thomas M. Sack, Ph.D., President and Chief Executive Officer. “We anticipate task orders this fall.”
This project is funded in whole or in part with Federal funds from the National Center for Advancing Translational Sciences at the National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271201700006I; Ref. No. N01TR-17-2201.
MRIGlobal, a not-for-profit research and development organization, delivers global solutions in national security and defense, energy and environment, life and animal sciences, agriculture and food safety, and transportation. The organization performs scientific research, advanced engineering and program integration and management for clients in government, industry and academia. Established in 1944 as Midwest Research Institute, MRIGlobal is one of two partners in the Alliance for Sustainable Energy, LLC, which manages and operates the National Renewable Energy Laboratory (NREL) in Golden, Colo., for the U.S. Department of Energy.
(Source: PR Newswire)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery